We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+32.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$343M
AUM Growth
+$158M
Cap. Flow
+$103M
Cap. Flow %
29.91%
Top 10 Hldgs %
65.57%
Holding
72
New
18
Increased
24
Reduced
6
Closed
20

Top Buys

Rank Stock Value
1
NUVA
NuVasive, Inc.
NUVA
+$17.6M
2
AMRN
Amarin Corp
AMRN
+$14.4M
3
DHR icon
Danaher
DHR
+$12.8M
4
EHTH icon
eHealth
EHTH
+$11.1M
5
GSK icon
GSK
GSK
+$10.9M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$5.19M
2
MRK icon
Merck
MRK
+$3.53M
3
ZGNX
Zogenix, Inc.
ZGNX
+$3.24M
4
TSRO
TESARO, Inc.
TSRO
+$2.67M
5
ABT icon
Abbott
ABT
+$2.27M

Sector Composition

Rank Sector Weight
1 Healthcare 86.25%
2 Industrials 8.36%
3 Financials 3.65%
4 Miscellaneous 1.46%
5 Real Estate 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
1
Amarin Corp
AMRN
$295M
$42.8M 12.48%
103,014
+39,844
+63% +$14.4M
GSK icon
2
GSK
GSK
$102B
$34.1M 9.94%
642,548
+218,961
+52% +$10.9M
RCM
3
DELISTED
R1 RCM Inc. Common Stock
RCM
$28.7M 8.36%
2,963,659
+614,353
+26% +$5.56M
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$27.3M 7.95%
495,429
-68,000
-12% -$3.24M
DHR icon
5
Danaher
DHR
$152B
$21M 6.12%
179,086
+125,163
+232% +$12.8M
NUVA
6
DELISTED
NuVasive, Inc.
NUVA
$18.8M 5.48%
+330,601
New +$17.6M
SNY icon
7
Sanofi
SNY
$107B
$14.7M 4.29%
332,402
+26,160
+9% +$1.12M
RDUS
8
DELISTED
Radius Health, Inc.
RDUS
$12.9M 3.75%
645,417
+93,364
+17% +$1.7M
EHTH icon
9
eHealth
EHTH
$38.4M
$12.5M 3.65%
+200,649
New +$11.1M
ASND icon
10
Ascendis Pharma A/S
ASND
$16.3B
$12.2M 3.55%
103,296
+88,042
+577% +$7.71M
SRPT icon
11
Sarepta Therapeutics
SRPT
$2.2B
$9.96M 2.91%
83,574
+43,080
+106% +$5.54M
ENSG icon
12
The Ensign Group
ENSG
$10.1B
$8.17M 2.38%
170,554
+79,074
+86% +$3.46M
ABMD
13
DELISTED
Abiomed Inc
ABMD
$7.81M 2.28%
27,339
+13,400
+96% +$4.45M
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$137B
$7.03M 2.05%
38,229
+1,737
+5% +$321K
FATE icon
15
Fate Therapeutics
FATE
$291M
$6.15M 1.79%
350,011
+185,011
+112% +$2.92M
TGTX icon
16
TG Therapeutics
TGTX
$8.26B
$6.02M 1.76%
748,594
+683,594
+1,052% +$3.69M
DCPH
17
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.81M 1.7%
250,432
+180,732
+259% +$4.73M
AERI
18
DELISTED
Aerie Pharmaceuticals
AERI
$5.45M 1.59%
114,779
-118,011
-51% -$5.19M
ARRY
19
DELISTED
Array Biopharma Inc
ARRY
$5.22M 1.52%
214,112
+123,700
+137% +$2.58M
ARGX icon
20
argenx
ARGX
$64B
$4.91M 1.43%
39,334
+1,110
+3% +$130K
ICPT
21
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$4.9M 1.43%
+43,800
New +$4.79M
PTCT icon
22
PTC Therapeutics
PTCT
$5.85B
$3.79M 1.1%
+100,600
New +$3.38M
ARNA
23
DELISTED
Arena Pharmaceuticals Inc
ARNA
$3.39M 0.99%
75,721
-5,650
-7% -$259K
BCRX icon
24
BioCryst Pharmaceuticals
BCRX
$2.51B
$3.36M 0.98%
412,876
+248,917
+152% +$2.13M
ARQL
25
DELISTED
Arqule Inc
ARQL
$3.1M 0.9%
646,918
+302,300
+88% +$1.17M
1
2 3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2019 Portfolio in Review

As of Q1 2019, Eversept Partners held 72 positions worth $343M, up 86% from $185M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Eversept Partners deployed $103M of net new capital in Q1 2019, opening 18 new positions and adding to 24 existing holdings. Its largest new stake was NuVasive, Inc.: 330,601 shares worth $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Aerie Pharmaceuticals, an estimated $5.19M trimmed.

  • Eversept Partners's largest Q1 2019 buy was NuVasive, Inc.: 330,601 shares worth $18.8M.
  • Eversept Partners added most to Amarin Corp in Q1 2019, an estimated $14.4M increase.
  • Eversept Partners's biggest Q1 2019 reduction was Aerie Pharmaceuticals, cutting an estimated $5.19M.
  • Eversept Partners fully exited Merck in Q1 2019, selling an estimated $3.53M.
  • Eversept Partners's ten largest holdings make up 66% of its $343M portfolio in Q1 2019.
  • Eversept Partners opened 18 new positions and closed 20 in Q1 2019.
  • Eversept Partners's portfolio value rose 86% quarter-over-quarter to $343M.

Based on Eversept Partners's 13F filing for Q1 2019, filed 14 May 2019.